Welcome to our dedicated page for Core Scientific SEC filings (Ticker: CORZR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Core Scientific's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Core Scientific's regulatory disclosures and financial reporting.
Two Seas Capital and related reporting persons now report beneficial ownership of 13,984,778 Core Scientific (CORZ) common shares, or 4.4% of the class. They state they ceased to be beneficial owners of more than five percent of the stock on April 23, 2026.
The position includes 313,646 shares issuable upon exercise of warrants and options to purchase 3,000,000 shares. These securities are held across affiliated funds and accounts that have delegated sole voting and investment power to Two Seas Capital under investment management agreements.
Two Seas Capital and related reporting persons now report beneficial ownership of 13,984,778 Core Scientific (CORZ) common shares, or 4.4% of the class. They state they ceased to be beneficial owners of more than five percent of the stock on April 23, 2026.
The position includes 313,646 shares issuable upon exercise of warrants and options to purchase 3,000,000 shares. These securities are held across affiliated funds and accounts that have delegated sole voting and investment power to Two Seas Capital under investment management agreements.
Core Scientific officer Todd M. Duchene sold shares in a planned transaction. On April 20, 2026, he completed an open-market sale of 10,000 shares of Core Scientific common stock at a weighted average price of $19.7952 per share under a Rule 10b5-1 trading plan adopted on December 5, 2025.
The shares were sold in multiple trades at prices ranging from $19.53 to $20.08. After this sale, Duchene directly holds 2,000,348 shares of Core Scientific common stock, indicating he retains a substantial equity position in the company.
Core Scientific officer Todd M. Duchene sold shares in a planned transaction. On April 20, 2026, he completed an open-market sale of 10,000 shares of Core Scientific common stock at a weighted average price of $19.7952 per share under a Rule 10b5-1 trading plan adopted on December 5, 2025.
The shares were sold in multiple trades at prices ranging from $19.53 to $20.08. After this sale, Duchene directly holds 2,000,348 shares of Core Scientific common stock, indicating he retains a substantial equity position in the company.
Core Scientific, Inc. plans a private offering of $3.3 billion in senior secured notes due 2031 through subsidiary Core Scientific Finance I LLC. The company expects the issuer to distribute proceeds back to Core Scientific, which plans to repay its delayed draw term loans under a 364‑day bridge credit facility.
Supplemental materials outline six licensed data center projects with CoreWeave, targeting about $7.8 billion in illustrative total revenue and roughly 590 MW of critical IT capacity, backed by long‑term power contracts and a completion guarantee from Core Scientific for project build‑out.
Core Scientific, Inc. plans a private offering of $3.3 billion in senior secured notes due 2031 through subsidiary Core Scientific Finance I LLC. The company expects the issuer to distribute proceeds back to Core Scientific, which plans to repay its delayed draw term loans under a 364‑day bridge credit facility.
Supplemental materials outline six licensed data center projects with CoreWeave, targeting about $7.8 billion in illustrative total revenue and roughly 590 MW of critical IT capacity, backed by long‑term power contracts and a completion guarantee from Core Scientific for project build‑out.
Core Scientific, Inc. executive Todd M. Duchene reported a tax-related share disposition linked to equity compensation. On this Form 4, 16,741 shares of common stock were withheld at $19.08 per share to satisfy withholding tax obligations when restricted stock units vested. After this non-market, tax-withholding disposition, Duchene directly holds 2,010,348 shares of common stock.
Core Scientific, Inc. executive Todd M. Duchene reported a tax-related share disposition linked to equity compensation. On this Form 4, 16,741 shares of common stock were withheld at $19.08 per share to satisfy withholding tax obligations when restricted stock units vested. After this non-market, tax-withholding disposition, Duchene directly holds 2,010,348 shares of common stock.
Core Scientific CEO Adam Taylor reported a routine tax-related share disposition. On the vesting of restricted stock units, 87,355 shares of Common Stock were withheld at $19.08 per share to cover withholding tax obligations.
After this non-market transaction, Taylor directly holds 4,470,033 shares of Core Scientific common stock. Because the shares were withheld for taxes rather than sold on the open market, this filing reflects compensation and tax mechanics more than a change in investment view.
Core Scientific CEO Adam Taylor reported a routine tax-related share disposition. On the vesting of restricted stock units, 87,355 shares of Common Stock were withheld at $19.08 per share to cover withholding tax obligations.
After this non-market transaction, Taylor directly holds 4,470,033 shares of Core Scientific common stock. Because the shares were withheld for taxes rather than sold on the open market, this filing reflects compensation and tax mechanics more than a change in investment view.
Two Seas Capital and affiliates filed an amended Schedule 13D reporting a 5.7% beneficial stake in Core Scientific, Inc. common stock. They collectively report beneficial ownership of 17,918,778 shares, including 313,646 shares issuable upon exercise of warrants and options to purchase 3,534,000 shares.
The position is held across a Strategic Fund, a Global Fund and separate Accounts, with voting and investment power delegated to Two Seas Capital under Investment Management Agreements. The filing also details a range of options positions with exercise prices between $10 and $27 and expirations on various dates in 2026, reflecting both purchased and written options tied to Core Scientific shares.
Two Seas Capital and affiliates filed an amended Schedule 13D reporting a 5.7% beneficial stake in Core Scientific, Inc. common stock. They collectively report beneficial ownership of 17,918,778 shares, including 313,646 shares issuable upon exercise of warrants and options to purchase 3,534,000 shares.
The position is held across a Strategic Fund, a Global Fund and separate Accounts, with voting and investment power delegated to Two Seas Capital under Investment Management Agreements. The filing also details a range of options positions with exercise prices between $10 and $27 and expirations on various dates in 2026, reflecting both purchased and written options tied to Core Scientific shares.
Core Scientific, Inc. officer Todd M. Duchene reported open-market sales of 10,000 shares of Common Stock on April 13, 2026, in two transactions pursuant to a Rule 10b5-1 trading plan adopted on December 5, 2025. The shares were sold at weighted average prices within ranges of $17.94–$18.90 and $18.97–$19.04 per share. Following these sales, Duchene directly holds 2,027,089 shares of Common Stock.
Core Scientific, Inc. officer Todd M. Duchene reported open-market sales of 10,000 shares of Common Stock on April 13, 2026, in two transactions pursuant to a Rule 10b5-1 trading plan adopted on December 5, 2025. The shares were sold at weighted average prices within ranges of $17.94–$18.90 and $18.97–$19.04 per share. Following these sales, Duchene directly holds 2,027,089 shares of Common Stock.
Core Scientific, Inc. officer Todd M. Duchene sold 10,000 shares of Common Stock in an open-market transaction at a weighted average price of $16.4865 per share. After this sale, he directly holds 2,037,089 shares. The trade was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025, and the shares were sold in multiple transactions at prices ranging from $16.285 to $16.78.
Core Scientific, Inc. officer Todd M. Duchene sold 10,000 shares of Common Stock in an open-market transaction at a weighted average price of $16.4865 per share. After this sale, he directly holds 2,037,089 shares. The trade was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 5, 2025, and the shares were sold in multiple transactions at prices ranging from $16.285 to $16.78.
Core Scientific, Inc. Chief Executive Officer Adam Taylor reported equity compensation activity involving performance-based restricted stock units (PSUs) and related tax withholding. On March 31, 2026, he acquired 741,545 shares of Common Stock at $0.00 per share upon vesting and settlement of previously granted PSUs tied to specified performance criteria.
On the same date, 315,307 shares of Common Stock were withheld at $14.96 per share to satisfy withholding tax obligations upon the vesting of restricted stock units, a non–open-market, tax-related disposition. After these transactions, Taylor directly held 4,557,388 shares of Common Stock, reflecting routine compensation and tax-settlement mechanics rather than open-market buying or selling.
Core Scientific, Inc. Chief Executive Officer Adam Taylor reported equity compensation activity involving performance-based restricted stock units (PSUs) and related tax withholding. On March 31, 2026, he acquired 741,545 shares of Common Stock at $0.00 per share upon vesting and settlement of previously granted PSUs tied to specified performance criteria.
On the same date, 315,307 shares of Common Stock were withheld at $14.96 per share to satisfy withholding tax obligations upon the vesting of restricted stock units, a non–open-market, tax-related disposition. After these transactions, Taylor directly held 4,557,388 shares of Common Stock, reflecting routine compensation and tax-settlement mechanics rather than open-market buying or selling.
Core Scientific, Inc. officer Todd M. Duchene reported a mix of equity compensation and share dispositions. On March 31, he received 216,734 shares of common stock through the settlement of performance-based restricted stock units, while 97,652 shares were withheld to cover tax obligations upon vesting.
On April 1, Duchene sold 10,000 shares of common stock in an open-market transaction at a weighted average price of $15.2523 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he directly holds 2,047,089 shares of Core Scientific common stock.
Core Scientific, Inc. officer Todd M. Duchene reported a mix of equity compensation and share dispositions. On March 31, he received 216,734 shares of common stock through the settlement of performance-based restricted stock units, while 97,652 shares were withheld to cover tax obligations upon vesting.
On April 1, Duchene sold 10,000 shares of common stock in an open-market transaction at a weighted average price of $15.2523 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he directly holds 2,047,089 shares of Core Scientific common stock.